ALMIRALL, S.A. «...678910...» Page 7 out of 16 07/06/2022 06:03 ALMIRALL, S.A. On business and financial situation Eight out of Ten Patients Maintained Skin Clearance at One Year in Lebrikizumab Atopic Dermatitis Monotherapy Trials Register number: 16634 03/06/2022 07:58 ALMIRALL, S.A. Other relevant information La Sociedad comunica información relativa al dividendo flexible Register number: 16592 18/05/2022 17:22 ALMIRALL, S.A. Liquidity and counterparty agreements Operaciones del contrato de liquidez durante el primer trimestre de 2022 Register number: 16344 09/05/2022 07:10 ALMIRALL, S.A. On business and financial situation Almirall files First Quarter results presentation for 2022 Register number: 16115 09/05/2022 07:05 ALMIRALL, S.A. On business and financial situation Almirall announces that will webcast a conference to introduce and explain the results for the first quarter of 2022 Register number: 16114 09/05/2022 06:58 ALMIRALL, S.A. Other relevant information La Sociedad comunica el calendario del dividendo flexible Register number: 16113 09/05/2022 06:55 ALMIRALL, S.A. Other relevant information La Sociedad comunica información relativa al dividendo flexible Register number: 16112 09/05/2022 06:51 ALMIRALL, S.A. On corporate governance Acuerdos adoptados por el Consejo de Administración Register number: 16111 09/05/2022 06:46 ALMIRALL, S.A. Announcement of general shareholders’ meeting Acuerdos adoptados en Junta General Ordinaria de la Sociedad Register number: 16110 11/04/2022 16:15 ALMIRALL, S.A. Other relevant information Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis Register number: 15561 Page 7 out of 16 «...678910...»
